In conclusion, our study demonstrates that cetuximab-IRDye800CW enables stable, tumor-specific, and high-contrast fluorescence imaging in colorectal cancer models, with performance closely linked to EGFR expression. The gene discussed is EGFR; the disease is colorectal cancer.